Blue Jet Healthcare Limited has informed the Exchange about Presentation
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare reported Q3 FY26 revenue of Rs. 1,924 mn, up 16% QoQ but down 40% YoY, with EBITDA at Rs. 469 mn (24% margin) and PAT at Rs. 402 mn (21% margin). On a YoY basis, EBITDA fell 62% and PAT fell 59%, mainly due to a sharp 89% drop in Pharma Intermediates sales caused by customer inventory de-stocking and order deferrals, plus a 73% decline in High-Intensity Sweeteners. Gross margin slipped to 52% from 55% on product mix change and a one-time inventory write-off. For 9M FY26, revenue rose 3% to Rs. 7,127 mn but EBITDA declined 6% to Rs. 2,228 mn (31% margin). On the positive side, the company completed a land purchase near Vizag, leased a 57,240 sq.ft. R&D center in Hyderabad for 10 years, and received CARE A1+/A+ credit ratings. Contrast Media remains the strongest segment, accounting for over 40% of revenue with 70% of sales under long-term contracts.
The sharp YoY earnings decline, especially in Pharma Intermediates and Sweeteners, along with margin compression, is likely to weigh negatively on the stock in the short term. However, the long-term Contrast Media positioning, debt-free balance sheet (cash and investments of Rs. 3,413 mn), and capacity expansion plans provide some support for a longer-term recovery story.